TY - JOUR AU - Bull, Emma C AU - Singh, Archana AU - Harden, Amy M AU - Soanes, Kirsty AU - Habash, Hala AU - Toracchio, Lisa AU - Carrabotta, Marianna AU - Schreck, Christina AU - Shah, Karan M AU - Riestra, Paulina Velasco AU - Chantoiseau, Margaux AU - Da Costa, Maria Eugénia Marques AU - Moquin-Beaudry, Gaël AU - Pantziarka, Pan AU - Essiet, Edidiong Akanimo AU - Gerrand, Craig AU - Gartland, Alison AU - Bojmar, Linda AU - Fahlgren, Anna AU - Marchais, Antonin AU - Papakonstantinou, Evgenia AU - Tomazou, Eleni M AU - Surdez, Didier AU - Heymann, Dominique AU - Cidre-Aranaz, Florencia AU - Fromigue, Olivia AU - Sexton, Darren W AU - Herold, Nikolas AU - Grünewald, Thomas G P AU - Scotlandi, Katia AU - Nathrath, Michaela AU - Green, Darrell TI - Targeting metastasis in paediatric bone sarcomas. JO - Molecular cancer VL - 24 IS - 1 SN - 1476-4598 CY - London PB - Biomed Central M1 - DKFZ-2025-01120 SP - 153 PY - 2025 AB - Paediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) comprise significant biological and clinical heterogeneity. This extreme heterogeneity affects response to systemic therapy, facilitates inherent and acquired drug resistance and possibly underpins the origins of metastatic disease, a key component implicit in cancer related death. Across all cancers, metastatic models have offered competing accounts on when dissemination occurs, either early or late during tumorigenesis, whether metastases at different foci arise independently and directly from the primary tumour or give rise to each other, i.e. metastases-to-metastases dissemination, and whether cell exchange occurs between synchronously growing lesions. Although it is probable that all the above mechanisms can lead to metastatic disease, clinical observations indicate that distinct modes of metastasis might predominate in different cancers. Around 70 KW - Humans KW - Bone Neoplasms: pathology KW - Bone Neoplasms: drug therapy KW - Child KW - Osteosarcoma: pathology KW - Osteosarcoma: drug therapy KW - Neoplasm Metastasis KW - Tumor Microenvironment: drug effects KW - Sarcoma, Ewing: pathology KW - Sarcoma, Ewing: drug therapy KW - Molecular Targeted Therapy KW - Biomarkers, Tumor KW - Prognosis KW - Bone (Other) KW - Ewing sarcoma (Other) KW - Metastasis (Other) KW - Osteosarcoma (Other) KW - Sarcoma (Other) KW - Biomarkers, Tumor (NLM Chemicals) LB - PUB:(DE-HGF)16 C6 - pmid:40442778 DO - DOI:10.1186/s12943-025-02365-z UR - https://inrepo02.dkfz.de/record/301728 ER -